Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits

Rhea-AI Summary

Harrow (Nasdaq: HROW) launched PharmaPack, a Direct-to-Prescriber cash-pay program on Feb 17, 2026, offering FDA-approved ophthalmic kits as affordable alternatives to compounded products.

Initial availability covers California, Mississippi, Arkansas, Connecticut, and Alabama, with nationwide expansion planned in the coming weeks.

Key Figures

Post-surgery use limit: 14 days post surgery Pre-surgery use limit: 1 day prior to surgery TOBRADEX ST concentration: 0.3% / 0.05% +5 more

8 metrics

Post-surgery use limit 14 days post surgery Recommended maximum duration for topical NSAID use like NEVANAC

Pre-surgery use limit 1 day prior to surgery Use beyond this window may increase corneal risk with topical NSAIDs

TOBRADEX ST concentration 0.3% / 0.05% Tobramycin and dexamethasone ophthalmic suspension strengths

Topical tobramycin ocular AEs <4% Most frequent adverse reactions to topical ocular tobramycin

Non-ocular adverse events 0.5% to 1% Reported rate with TOBRADEX ST use

MKO Melt users millions of Americans each year Patients needing cataract-related infection and pain control therapies

Initial states 5 states California, Mississippi, Arkansas, Connecticut, Alabama for PharmaPack launch

Corneal risk window beyond 14 days Extended topical NSAID use may increase corneal adverse event risk

Market Reality Check

Price: $47.69 Vol: Volume 319,921 vs 20-day ...

low vol

$47.69 Last Close

Volume Volume 319,921 vs 20-day average 517,835 – below typical activity. low

Technical Price $47.69 is above 200-day MA $38.48, and 13.05% below 52-week high of $54.85.

Peers on Argus

HROW gained 1.21% on this cash-pay program news. Among key peers, AMPH rose 2.44...

1 Up

HROW gained 1.21% on this cash-pay program news. Among key peers, AMPH rose 2.44%, PAHC rose 1.06%, AVDL and BGM were flat, and BCRX fell 1.6%. Only one peer (BCRX) appeared in the momentum scanner, moving up separately without related news, suggesting HROW’s move was stock-specific rather than a coordinated sector rotation.

Historical Context

5 past events · Latest: Feb 03 (Negative)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 03	Regulatory / licensing	Negative	+5.1%	ImprimisRx exited California and paid an administrative fine after regulatory matters.
Feb 02	Guidance & operations	Positive	+9.7%	Reaffirmed 2025 revenue guidance and announced sales force and product expansions.
Nov 24	Investor conferences	Neutral	+0.2%	Planned management presentations at two December 2025 investor conferences.
Nov 18	Acquisition closing	Positive	-1.4%	Closed acquisition of Melt Pharmaceuticals and added MELT clinical-stage candidates.
Nov 10	Earnings report	Positive	+0.6%	Reported strong Q3 2025 revenue growth and positive adjusted EBITDA with profitability.

Pattern Detected

Recent news often saw positive price reactions to growth and guidance updates, with mixed reactions around acquisitions and regulatory/competitive developments.

Recent Company History

Over the last five reported events, Harrow navigated earnings, guidance, acquisitions, and regulatory items. Q3 2025 results showed strong revenue growth and a swing to quarterly profitability on November 10, 2025, followed by closing the Melt Pharmaceuticals acquisition on November 18, 2025. In early February 2026, Harrow reaffirmed 2025 revenue guidance and addressed California regulatory changes tied to ImprimisRx. The PharmaPack launch extends that focus on branded ophthalmic access and distribution.

Market Pulse Summary

This announcement outlined Harrow’s PharmaPack cash-pay program, aimed at expanding access to FDA-ap...

Analysis

This announcement outlined Harrow’s PharmaPack cash-pay program, aimed at expanding access to FDA-approved ophthalmic brands as alternatives to compounded products, initially across 5 states with plans to expand. It followed recent milestones including strong Q3 2025 results, reaffirmed revenue guidance, and the Melt Pharmaceuticals acquisition. Investors may watch adoption trends for PharmaPack, competitive responses in cataract care, and future updates on branded ophthalmic portfolio performance.

Key Terms

ophthalmic, nonsteroidal anti-inflammatory drugs, nsaids, keratitis, +2 more

6 terms

ophthalmic medical

"a leading provider of ophthalmic disease management solutions in North America"

Relating to the eye and its care, including medicines, drops, diagnostic tools and surgical devices used to prevent, diagnose or treat eye conditions. Investors care because ophthalmic products form a distinct market with specialized safety approvals, manufacturing needs and payer coverage, so success or failure in this area can drive steady revenue or costly setbacks—think of it as a niche, high‑safety consumer product line for vision health.

nonsteroidal anti-inflammatory drugs medical

"With some nonsteroidal anti-inflammatory drugs including NEVANAC®, there exists the potential"

Nonsteroidal anti-inflammatory drugs are medicines that reduce pain, fever and swelling by blocking chemicals that cause inflammation, like common over-the-counter and prescription pain relievers. For investors, they matter because changes in safety data, regulatory approvals, patent status or competition can quickly alter sales, liabilities and market share—similar to how a recall or new model can reshape fortunes in a product market.

nsaids medical

"Topical nonsteroidal anti-inflammatory drugs (NSAIDs) including NEVANAC®, may slow or delay healing."

Nonsteroidal anti-inflammatory drugs are a class of medicines used to reduce pain, fever, and inflammation; common examples include ibuprofen and naproxen. They matter to investors because they drive large, predictable sales across over‑the‑counter and prescription markets but are closely watched for safety issues, regulatory decisions, and generic competition—like widely used household tools whose recalls or lost exclusivity can quickly change a company’s revenue outlook.

keratitis medical

"Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use"

Keratitis is inflammation or irritation of the cornea, the clear front surface of the eye responsible for focusing vision; it can cause pain, redness, blurred vision, light sensitivity or a feeling of something in the eye. For investors, keratitis matters because it drives demand for treatments, diagnostics and medical devices, and influences clinical trial outcomes and regulatory decisions in ophthalmology—think of the cornea as a camera lens that must stay clear for the picture to be sharp.

intraocular pressure medical

"Intraocular Pressure (IOP) Increase—Prolonged use may result in glaucoma"

Intraocular pressure is the fluid pressure inside the eye, similar to the air pressure in a tire or the tension in a water balloon that helps the eye keep its shape. It matters to investors because sustained high pressure can lead to glaucoma and vision loss, driving demand for drugs, surgical devices, diagnostics and related regulatory approvals and reimbursements, which directly affect company revenues and risk profiles.

aminoglycosides medical

"Aminoglycosides: Neurotoxicity, ototoxicity, and nephrotoxicity have occurred"

Aminoglycosides are a well-established class of powerful antibiotics used mainly in hospitals to treat serious bacterial infections. Investors should care because their clinical effectiveness, safety risks (notably kidney and hearing damage), regulatory approvals, manufacturing quality, and emerging bacterial resistance all directly affect product sales, liability exposure, and the commercial value of companies developing or selling these drugs—think of them as heavy-duty tools that carry both strong benefits and notable risks.

AI-generated analysis. Not financial advice.

PharmaPack Program to Expand Access to Affordable, FDA-Approved Branded Ophthalmic Therapies

NASHVILLE, Tenn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of a new Direct-to-Prescriber (DTP) cash-pay offering called PharmaPack, which expands the Company’s commitment to offering affordable FDA-approved branded products as alternatives to off-label compounded formulations.

PharmaPack kits expand access to FDA-approved ophthalmic products for the millions of Americans each year who require infection control and treatment of pain and inflammation associated with cataract surgery. PharmaPack kits also remove insurance-related administrative complexity and reduce regulatory and medical-legal risk associated with off-label compounded products. Harrow will offer the following PharmaPack kits at affordable and 100% transparent pricing:

“Harrow’s PharmaPack program addresses a long-standing challenge in ophthalmology—providing patients with FDA-approved therapies that are both reliable and affordable,” said Scott Spector, MD. “The combination of trusted branded products, pricing transparency, and these compelling cash-pay prices is encouraging and supports complexity-free prescribing and greater confidence when considering FDA-approved branded alternatives to compounded products. Given the strength of this offering and the value it represents, I have already ordered PharmaPack Prime for my patients.”

“Access to FDA-approved therapies at affordable, transparent prices is something optometrists have been asking for,” said Maria Pribis, OD. “PharmaPack helps close that gap by making high-quality branded products more attainable for everyday patient care.”

How to Order:

PharmaPack kits will initially be available in California, Mississippi, Arkansas, Connecticut, and Alabama, with plans to expand nationwide in the coming weeks. Prescribers can access PharmaPack offerings from the home screen of their account dashboard, or through the following links:

• PharmaPack Max
• PharmaPack Prime

Contact your Harrow or ImprimisRx representative with any questions, or email PharmaPack@HarrowInc.com.

About NEVANAC^®

INDICATION AND USAGE
NEVANAC ophthalmic suspension is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery.

CONTRAINDICATIONS
Hypersensitivity to any of the ingredients in the formula or to other NSAIDS.

WARNINGS & PRECAUTIONS

• Increased Bleeding Time: With some nonsteroidal anti-inflammatory drugs including NEVANAC^®, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied nonsteroidal anti-inflammatory drugs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery. It is recommended that NEVANAC^® ophthalmic suspension be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.
• Delayed Healing: Topical nonsteroidal anti-inflammatory drugs (NSAIDs) including NEVANAC^®, may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.
• Corneal Effects: Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs including NEVANAC^® and should be closely monitored for corneal health.
  

Postmarketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients.

Postmarketing experience with topical NSAIDs also suggests that use more than 1 day prior to surgery or use beyond 14 days post surgery may increase patient risk and severity of corneal adverse events.

• Contact Lens Wear: NEVANAC should not be administered while using contact lenses.
  

ADVERSE REACTIONS
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Please see additional Important Safety Information throughout and the enclosed full Prescribing Information.

About TOBRADEX^® ST

INDICATION AND USAGE
TOBRADEX ST (tobramycin and dexamethasone ophthalmic suspension) 0.3%/0.05% is a topical antibiotic and corticosteroid combination for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.

Important Safety Information

CONTRAINDICATIONS:
Most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and also in mycobacterial infection of the eye and fungal disease of ocular structures. Hypersensitivity to any components of the medication.

WARNINGS & PRECAUTIONS:

• Intraocular Pressure (IOP) Increase—Prolonged use may result in glaucoma with damage to the optic nerve, and defects in visual acuity and fields of vision. IOP should be monitored.
• Aminoglycoside Sensitivity—Sensitivity to topically applied aminoglycosides may occur.
• Cataracts—Posterior subcapsular cataract formation may occur.
• Delayed Healing—May delay healing and increase the incidence of bleb formation. Perforations of the cornea or sclera have occurred. Slit lamp biomicroscopy and fluorescein staining should be conducted.
• Bacterial Infections—May suppress host response and increase secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection. If signs and symptoms fail to improve after 2 days, then the patient should be re-evaluated.
• Viral Infections—Use with a history of herpes simplex requires great caution. The course and severity of many viral infections of the eye (including herpes simplex) may be exacerbated.
• Fungal Infections—Fungal infections of the cornea may occur and should be considered in any persistent corneal ulceration.
• Vision Blurred—Vision may be temporarily blurred following dosing with TOBRADEX^® ST. Care should be exercised in operating machinery or driving a motor vehicle.
• Risk of Contamination—Do not touch the dropper tip of the bottle to any surface, as this may contaminate the contents.
• Contact Lens Use—TOBRADEX^® ST contains benzalkonium chloride, an antimicrobial preservative, which may be absorbed by soft contact lenses. Contact lenses should not be worn during the use of TOBRADEX^® ST.

ADVERSE REACTIONS:

• The most frequent adverse reactions (<4%) to topical ocular tobramycin are hypersensitivity and localized ocular toxicity, including eye pain, eyelid pruritus, eyelid edema, and conjunctival hyperemia.
• The reactions due to the steroid component are increased IOP with possible damage to optic nerve and development of glaucoma, subcapsular cataract, and impaired healing.
• The development of secondary infection has occurred. Fungal infections of the cornea may occur. Secondary bacterial ocular infection following suppression of host responses also occurs.
• Non-ocular adverse events (0.5% to 1%) included headache and increased blood pressure.

The following additional adverse reactions have been reported with the individual components below:

• Aminoglycosides: Neurotoxicity, ototoxicity, and nephrotoxicity have occurred in patients receiving systemic aminoglycoside therapy. Aminoglycosides may aggravate muscle weakness in patients with known or suspected neuromuscular disorders, such as myasthenia gravis or Parkinson’s disease, because of their potential effect on neuromuscular function.
• Dexamethasone: Cushing’s syndrome and adrenal suppression may occur after the use of dexamethasone in excess of the listed dosing instructions in predisposed patients, including children and patients treated with CYP3A4 inhibitors.

Please see the full Prescribing Information.

About MAXITROL^®

INDICATIONS AND USAGE:

• For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists.
• Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies.
• The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye.
• The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa.
• This product does not provide adequate coverage against: Serratia marcescens and Streptococci, including Streptococcus pneumoniae.
  

CONTRAINDICATIONS:
Maxitrol is contraindicated in patients with epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, varicella, and many other viral infections of the cornea and conjunctiva, mycobacterial infections of the eye, fungal diseases of ocular structures, as well as hypersensitivity to any component of the medication.

WARNINGS:

• Maxitrol should not be injected or intraocularly administered.
• Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye. Prolonged use may result in glaucoma, with damage to the optic nerve, defects in visual acuity and fields of vision, and posterior subcapsular cataract formation. Prolonged use may suppress the host response and thus increase the hazard of secondary ocular infection.
• If this product is used for 10 days or longer, intraocular pressure should be routinely monitored.
• Neomycin sulfate may cause cutaneous sensitization. Sensitivity to topically administered aminoglycosides, such as neomycin, may occur in some patients. If hypersensitivity develops, treatment should be discontinued. Cross hypersensitivity to other aminoglycosides can occur, and the possibility that patients who become sensitized to topical neomycin may also be sensitive to other topical and/or systemic aminoglycosides should be considered.

PRECAUTIONS:
If inflammation or pain persists longer than 48 hours or becomes aggravated, the patient should discontinue use and consult a physician. Patients should be advised that their vision may be temporarily blurred following dosing with Maxitrol.

ADVERSE REACTIONS:
Reactions occurring most often from the presence of the anti-infective ingredient are allergic sensitizations. The reactions due to the steroid component are: elevation of intraocular pressure (IOP) with possible development of glaucoma, and infrequent optic nerve damage; posterior subcapsular cataract formation; and delayed wound healing.

To view the Full Prescribing Information for Maxitrol, please visit maxitrolrx.com/prescribinginformation.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading provider of ophthalmic disease management solutions in North America, offering a comprehensive portfolio of products that address conditions affecting both the front and back of the eye, such as dry eye disease, wet (or neovascular) age-related macular degeneration, cataracts, refractive errors, glaucoma and a range of other ocular surface conditions and retina diseases. Harrow was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance patient compliance and improve clinical outcomes. For more information about Harrow, please visit harrow.com and connect with us on LinkedIn.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered “forward-looking statements.” Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties, which may cause results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include, among others, risks related to: liquidity or results of operations; our ability to successfully implement our business plan, develop and commercialize our products, product candidates and proprietary formulations in a timely manner or at all, identify and acquire additional products, manage our pharmacy operations, service our debt, obtain financing necessary to operate our business, recruit and retain qualified personnel, manage any growth we may experience and successfully realize the benefits of our previous acquisitions and any other acquisitions and collaborative arrangements we may pursue; competition from pharmaceutical companies, outsourcing facilities and pharmacies; general economic and business conditions, including inflation and supply chain challenges; regulatory and legal risks, including litigation matters, and other uncertainties related to our pharmacy operations and the pharmacy and pharmaceutical business in general; physician interest in and market acceptance of our current and any future formulations and compounding pharmacies generally. These and additional risks and uncertainties are more fully described in Harrow’s filings with the Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the year ended December 31, 2024, subsequent Quarterly Reports on Form 10-Q, and other filings with the SEC. Such documents may be read free of charge on the SEC’s website at sec.gov. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. Except as required by law, Harrow undertakes no obligation to update any forward-looking statements to reflect new information, events, or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

Contacts:

Mike Biega
Vice President of Investor Relations and Communications
mbiega@harrowinc.com
617-913-8890

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/65f1b48d-ca95-4242-a307-f68011e16b38

FAQ

What is Harrow's PharmaPack launch (HROW) announced on Feb 17, 2026?

PharmaPack is a cash-pay Direct-to-Prescriber program offering FDA-approved ophthalmic kits at transparent prices. According to Harrow, the program provides branded alternatives to off-label compounded products to simplify prescribing and reduce regulatory and medical-legal risk.

Which PharmaPack kits will Harrow (HROW) offer and how do they help patients?

Harrow will offer PharmaPack Prime and PharmaPack Max kits for post-cataract infection control, pain, and inflammation. According to Harrow, these kits expand access to trusted branded therapies and remove insurance-related administrative complexity for prescribers and patients.

When and where will PharmaPack from Harrow (HROW) be available to prescribers?

PharmaPack is available starting Feb 17, 2026, initially in CA, MS, AR, CT, and AL, with nationwide expansion planned. According to Harrow, prescribers can order via their account dashboard or contact Harrow/ImprimisRx representatives for access.

How does PharmaPack affect prescribing compared with compounded ophthalmic products for HROW investors?

PharmaPack aims to encourage prescribing of FDA-approved branded therapies instead of off-label compounded products by offering transparent cash-pay pricing. According to Harrow, this reduces administrative burden and potential regulatory and medical-legal exposure associated with compounding.

Does PharmaPack include specific branded drugs such as Nevanac or Tobradex ST in HROW's offering?

Yes, PharmaPack kits reference FDA-approved branded ophthalmic therapies, including products like Nevanac and Tobradex ST for post-surgical pain, inflammation, and infection control. According to Harrow, these branded options are incorporated into the kits to improve access.

How can prescribers order PharmaPack kits from Harrow (HROW) and who can they contact?

Prescribers can order PharmaPack via the Harrow account dashboard or provided product links for PharmaPack Prime and Max. According to Harrow, questions may be directed to Harrow or ImprimisRx representatives or emailed to PharmaPack@HarrowInc.com.